Foghorn Therapeutics (FHTX) Competitors $5.28 +0.22 (+4.35%) Closing price 04:00 PM EasternExtended Trading$5.28 +0.00 (+0.09%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock FHTX vs. XERS, PGEN, ELVN, COLL, CVAC, PHVS, CALT, LENZ, ZYME, and GPCRShould you be buying Foghorn Therapeutics stock or one of its competitors? The main competitors of Foghorn Therapeutics include Xeris Biopharma (XERS), Precigen (PGEN), Enliven Therapeutics (ELVN), Collegium Pharmaceutical (COLL), CureVac (CVAC), Pharvaris (PHVS), Calliditas Therapeutics AB (publ) (CALT), LENZ Therapeutics (LENZ), Zymeworks (ZYME), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry. Foghorn Therapeutics vs. Its Competitors Xeris Biopharma Precigen Enliven Therapeutics Collegium Pharmaceutical CureVac Pharvaris Calliditas Therapeutics AB (publ) LENZ Therapeutics Zymeworks Structure Therapeutics Foghorn Therapeutics (NASDAQ:FHTX) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment. Is FHTX or XERS more profitable? Xeris Biopharma has a net margin of -13.01% compared to Foghorn Therapeutics' net margin of -311.90%. Company Net Margins Return on Equity Return on Assets Foghorn Therapeutics-311.90% N/A -28.00% Xeris Biopharma -13.01%N/A -8.00% Which has preferable valuation & earnings, FHTX or XERS? Xeris Biopharma has higher revenue and earnings than Foghorn Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFoghorn Therapeutics$22.60M13.21-$86.62M-$1.19-4.44Xeris Biopharma$203.07M6.30-$54.84M-$0.21-37.71 Does the media refer more to FHTX or XERS? In the previous week, Xeris Biopharma had 9 more articles in the media than Foghorn Therapeutics. MarketBeat recorded 13 mentions for Xeris Biopharma and 4 mentions for Foghorn Therapeutics. Xeris Biopharma's average media sentiment score of 1.27 beat Foghorn Therapeutics' score of 1.09 indicating that Xeris Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Foghorn Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xeris Biopharma 10 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer FHTX or XERS? Foghorn Therapeutics presently has a consensus target price of $10.67, suggesting a potential upside of 102.02%. Xeris Biopharma has a consensus target price of $7.08, suggesting a potential downside of 10.56%. Given Foghorn Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Foghorn Therapeutics is more favorable than Xeris Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Foghorn Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.17Xeris Biopharma 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals & insiders hold more shares of FHTX or XERS? 61.6% of Foghorn Therapeutics shares are owned by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are owned by institutional investors. 7.6% of Foghorn Therapeutics shares are owned by insiders. Comparatively, 4.6% of Xeris Biopharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, FHTX or XERS? Foghorn Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. SummaryFoghorn Therapeutics and Xeris Biopharma tied by winning 8 of the 16 factors compared between the two stocks. Get Foghorn Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FHTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FHTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FHTX vs. The Competition Export to ExcelMetricFoghorn TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$286.04M$3.12B$5.75B$9.77BDividend YieldN/A2.28%6.66%4.50%P/E Ratio-4.447.4762.2622.40Price / Sales13.21396.81537.34111.77Price / CashN/A43.5325.7028.92Price / Book-3.888.1011.196.58Net Income-$86.62M-$53.35M$3.28B$265.84M7 Day Performance-4.52%-0.14%0.15%-0.07%1 Month Performance5.81%9.18%8.34%5.83%1 Year Performance-36.23%7.53%54.21%17.88% Foghorn Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FHTXFoghorn Therapeutics2.7561 of 5 stars$5.28+4.3%$10.67+102.0%-38.9%$286.04M$22.60M-4.44120News CoveragePositive NewsXERSXeris Biopharma3.5507 of 5 stars$7.77+0.3%$7.08-8.8%+178.6%$1.25B$203.07M-37.00290Positive NewsShort Interest ↓PGENPrecigen4.271 of 5 stars$3.98-4.8%$8.25+107.3%+310.0%$1.25B$3.92M-9.48190ELVNEnliven Therapeutics2.7799 of 5 stars$19.94-4.4%$41.20+106.6%-7.4%$1.24BN/A-9.9750News CoverageCOLLCollegium Pharmaceutical2.8473 of 5 stars$38.77-0.9%$42.33+9.2%+0.9%$1.23B$631.45M37.28210Positive NewsCVACCureVac4.4724 of 5 stars$5.40-0.7%$6.83+26.5%+71.0%$1.21B$510.51M5.63880Positive NewsPHVSPharvaris2.8535 of 5 stars$23.65+2.3%$35.60+50.5%+20.3%$1.21BN/A-7.0430CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180LENZLENZ Therapeutics1.6074 of 5 stars$39.68-0.8%$49.60+25.0%+65.2%$1.14BN/A-20.88110ZYMEZymeworks0.0439 of 5 stars$14.57-3.5%N/AN/A$1.14B$76.30M-15.02460News CoverageGap DownGPCRStructure Therapeutics2.3311 of 5 stars$18.57-5.3%$75.71+307.7%-49.4%$1.13BN/A-17.69136News CoveragePositive News Related Companies and Tools Related Companies Xeris Biopharma Competitors Precigen Competitors Enliven Therapeutics Competitors Collegium Pharmaceutical Competitors CureVac Competitors Pharvaris Competitors Calliditas Therapeutics AB (publ) Competitors LENZ Therapeutics Competitors Zymeworks Competitors Structure Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FHTX) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredDid you spot this in the Oval Office last week?When Tim Cook stood in the Oval Office last week, all eyes were on the "unique 24K gold gift" he presented to ...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Foghorn Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Foghorn Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FHTX Stock Alerts